Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 3/20 | 0.40 |
| ▸ | SPR | P35270 | 2/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 7/20 | 0.36 |
| ▸ | LCK | P06239 | 1/20 | 0.36 |
| ▸ | KIT | P10721 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.34 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1884775 | 0.80 | MAPK14 (0.41) | MAPK14MAPKAPK2 | |
| SCHEMBL7079274 | 0.75 | RAB9A (0.49) | TP53MAPK14L3MBTL1THRBGLA | |
| SCHEMBL25343811 | 0.73 | CYP17A1 (0.38) | TP53MAPK14L3MBTL1CYP17A1CYP1A2 | |
| SCHEMBL10612189 | 0.72 | L3MBTL1 (0.43) | TP53SPRMAPK14LCKKIT | |
| SCHEMBL30568558 | 0.71 | CYP11B2 (0.40) | MAPK14GAACYP17A1CYP1A2 | |
| SCHEMBL3671793 | 0.69 | MAPK14 (0.42) | MAPK14LCKKITKDRMAPKAPK2 | |
| SCHEMBL29703261 | 0.69 | NPC1 (0.54) | TP53L3MBTL1GLA | |
| SCHEMBL3673264 | 0.67 | MAPK14 (0.42) | MAPK14LCKKITKDRMAPKAPK2 | |
| SCHEMBL25343005 | 0.67 | PDE9A (0.44) | L3MBTL1CYP17A1CYP1A2 | |
| SCHEMBL25343768 | 0.67 | PDE9A (0.46) | L3MBTL1CYP17A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7846944-B2 | Pyrazolo-pyridinone compounds and methods of use thereof | AMGEN INC. (US) | 2010-12-07 | — | — | US | disclosed |
| US-20090012299-A1 | Pyrazolo-pyridinone compounds and methods of use thereof | AMGEN INC. (US) | 2009-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012299-A1 | Pyrazolo-pyridinone compounds and methods of use thereof | MAPK1, MAP3K1, MAP4K2 | TP53 2023/4885SPR 1892/4885MAPK14 41/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.